A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

Publication date: Jan 30, 2025

The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called “s3”, which was designed to improve the body’s response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does “s3” lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.

Concepts	Keywords
Breastfeeding2	COVID-19
California	SARS-CoV-2
Organ	vaccine
Phlebotomy15
Vaccine

Semantics

Type	Source	Name
disease	MESH	COVID-19
disease	IDO	blood
drug	DRUGBANK	Methionine
disease	IDO	cell
drug	DRUGBANK	Creatinine
drug	DRUGBANK	Chorionic Gonadotropin (Human)
drug	DRUGBANK	Follitropin
disease	IDO	intervention
pathway	REACTOME	SARS-CoV-2 Infection
disease	IDO	nucleic acid
disease	MESH	Hepatitis B
pathway	KEGG	Hepatitis B
drug	DRUGBANK	Hepatitis B Vaccine (Recombinant)
disease	MESH	hepatitis C
pathway	KEGG	Hepatitis C
disease	MESH	infection
disease	IDO	history
disease	MESH	thrombosis
disease	MESH	thrombocytopenia
disease	MESH	syndrome
disease	MESH	immune thrombocytopenia
disease	MESH	capillary leak syndrome
disease	MESH	genetic disorders
disease	MESH	autoimmune disease
disease	MESH	myocarditis
disease	MESH	pericarditis
disease	MESH	bleeding
disease	MESH	contraindication
disease	MESH	chronic illness
disease	MESH	hypertension
disease	MESH	psychiatric illness
disease	IDO	site
drug	DRUGBANK	Aspartame
drug	DRUGBANK	Prednisone
drug	DRUGBANK	Methotrexate
drug	DRUGBANK	Rituximab
disease	MESH	cancer
disease	MESH	melanoma
pathway	KEGG	Melanoma
disease	MESH	skin cancers
pathway	KEGG	Primary immunodeficiency
disease	IDO	primary immunodeficiency
disease	MESH	complications
disease	MESH	morbidity

Original Article

(Visited 3 times, 1 visits today)